Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
World game at war: why some European nations have threatened a World Cup boycott 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
WALTHAM, Mass., April 18, 2018 -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will present a scientific poster at the upcoming 2018 American Academy of Neurology (AAN) Annual Meeting to be held in Los Angeles, CA, April 21-27.
The poster is titled: “Pilot Study of Sleep/Wake Classification by Leg-Worn Actigraphy”, which can be viewed here: Pilot Study of Sleep/Wake Classification by Leg-Worn Actigraphy.
The purpose of this study was to assess the accuracy of the sleep monitoring technology in the Quell® device by comparison to gold standard polysomnography. The study was conducted in collaboration with Dr. John Winkelman of the Massachusetts General Hospital, Boston, MA.
"Most people with chronic pain have deficient sleep. Quell monitors the user’s sleep to provide objective feedback on this important outcome and to automatically adjust stimulation to optimize comfort and pain relief. This study evaluated the accuracy of the monitoring technology in patients with sleep disorders,” said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. “We are pleased with the results and have identified several opportunities for improvement.”
About Quell
Quell is an advanced, wearable technology for treating chronic pain. It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription. Quell users can personalize and manage therapy discreetly via the Quell app. Quell also offers health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell users can synchronize their data with the Quell Health Cloud, which provides customized feedback and powers one of the world’s largest chronic pain databases. Quell is available online and through select
retailers. Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
[email protected]
